

S5 Table. OS and 1-year conditional survival estimates of each BCLC subgroups using initial treatment methods in cohort B

	BCLC 0		Surgery		LT		Local ablation		Transarterial Tx		Systemic CTx		RTx		BSC	
	OS	1YR CSE	OS	1YR CSE	OS	1YR CSE	OS	1YR CSE	OS	1YR CSE	OS	1YR CSE	OS	1YR CSE	OS	1YR CSE
BCLC 0																
No. (%)	296 (10.9)		61 (20.6)		3 (1.0)		122 (41.2)		103 (34.8)		0.0%		0.0%		7 (2.4)	
at 6mo	99.0	96.6	100.0	100.0	100.0	100.0	99.2	99.2	99.0	91.2					85.7	100.0
at 1YR	97.3	96.6	100.0	100.0	100.0	100.0	99.2	97.5	94.2	90.7					85.7	100.0
at 18mo	95.6	94.5	100.0	100.0	100.0	-	98.4	95.7	90.3	88.8					85.7	100.0
at 2YR	93.2	92.9	100.0	97.4	100.0		96.7	91.6	85.4	90.8					85.7	100.0
at 30mo	90.3	95.9	100.0	97.4	-		94.1	94.2	80.2	96.7					85.7	100.0
at 3YR	86.6	100.0	97.4	100.0			88.6	100.0	77.5	100.0					85.7	-
at 42mo	86.6		97.4				88.6		77.5						85.7	
at 4YR	86.6		97.4				88.6		77.5						-	
BCLC A																
No. (%)	1118 (41.1)		365 (32.6)		12 (1.1)		184 (16.5)		485 (43.4)		5 (0.4)		1 (0.1)		66 (5.9)	
6mo	96.0	89.8	97.0	96.9	100.0	91.7	98.9	92.3	96.1	85.8	60.0	33.3	100.0		83.3	74.5
1YR	91.2	86.6	95.9	94.3	100.0	83.3	95.1	92.0	89.5	79.7	20.0	100.0	-		72.7	65.3
18mo	86.2	86.1	94.0	93.9	91.7	90.9	91.3	91.0	82.5	78.2	20.0	-			62.1	64.5
2YR	79.0	87.2	90.4	94.5	83.3	100.0	87.5	88.0	71.3	80.3	20.0				47.5	84.4
30mo	74.2	87.3	88.2	95.2	83.3	100.0	83.0	90.0	64.5	77.6	-				40.1	-
3YR	68.9	85.7	85.5	96.9	83.3	-	77.0	97.1	57.3	67.2					40.1	
42mo	64.8		84.0	-	83.3		74.8		50.1						-	
4YR	59.0		82.8		-		74.8		38.5							
BCLC B																
No. (%)	319 (11.7)		40 (12.5)		7 (2.2)		7 (2.2)		208 (65.2)		8 (2.5)		1 (0.3)		48 (15.0)	
6mo	85.6%	77.3	92.5	97.3	85.7	100.0	100.0	71.4	90.4	77.1	62.5	0.0	100.0	100.0	58.3	64.3
1YR	74.6	76.1	92.5	94.6	85.7	100.0	85.7	83.3	79.3	73.9	25.0		100.0	100.0	43.8	61.9
18mo	66.1	75.9	90.0	91.6	85.7	83.3	71.4	100.0	69.7	73.3	0.0		100.0	0.0	37.5	66.2

2YR	56.7	76.4	87.5	83.9	85.7	83.3	71.4	80.0	58.7	72.4		100.0	27.1	91.7		
30mo	50.2	75.8	82.4	79.2	71.4	-	71.4	53.3	51.1	73.1		0.0	24.8	100.0		
3YR	43.4	74.5	73.4	88.9	71.4		57.1	-	42.5	76.1			24.8	0.0		
42mo	38.0		65.3	-	-		38.1		37.3				24.8			
4YR	32.3		65.3				-		32.3				0.0			
BCLC C																
No. (%)	870 (32.0)	97 (11.1)	6 (0.7)	26 (3.0)	407 (46.8)	129 (14.8)	27 (3.1)	178 (20.5)								
6mo	59.1	59.5	94.8	85.9	100.0	83.3	92.3	87.5	72.2	57.1	36.4	38.3	51.9	14.3	20.8	35.1
1YR	43.7	73.9	88.7	91.9	100.0	83.3	88.5	86.7	52.8	68.8	17.8	60.9	14.8	50.0	12.9	52.2
18mo	35.2	82.3	81.4	97.3	83.3	100.0	80.8	95.0	41.3	74.7	14.0	71.3	7.4	50.0	7.3	92.3
2YR	32.3	79.5	81.4	93.1	83.3	100.0	76.7	100.0	36.4	72.2	10.9	61.1	7.4	50.0	6.7	76.4
30mo	29.0	79.9	79.2	90.0	83.3	100.0	76.7	100.0	30.8	71.2	9.9	66.7	3.7	-	6.7	76.4
3YR	25.7	90.1	75.8	94.0	83.3	-	76.7	-	26.3	83.7	6.6	-	3.7		5.1	-
42mo	23.1		71.3		83.3		76.7		22.0		6.6		-		5.1	
4YR	23.1		71.3		-		-		22.0		-				-	
BCLC D																
No. (%)	118 (4.3)	4 (3.4)	5 (4.2)	11 (9.3)	36 (30.5)	9 (7.6)	4 (3.4)	49 (41.5)								
6mo	45.8	64.8	75.0	100.0	80.0	100.0	100.0	72.7	69.4	68.0	22.2	50.0	0.0	-	18.4	22.2
1YR	37.3	70.5	75.0	100.0	80.0	100.0	90.9	60.0	58.3	76.2	22.2	50.0			8.2	25.0
18mo	29.7	69.5	75.0	100.0	80.0	0.0	72.7	50.0	47.2	87.8	11.1	0.0			4.1	-
2YR	26.3	72.5	75.0	100.0	80.0		54.5	-	44.4	84.0	11.1				2.0	
30mo	20.6	92.3	75.0	100.0	0.0		36.4		41.5	90.0	0.0				-	
3YR	19.0	-	75.0	-			-		37.3	-						
42mo	19.0%	-	75.0%						37.3%							
4YR	-		-						-							

Values are presented as percentage unless otherwise indicated. OS, overall survival; BCLC, Barcelona-clinic liver cancer; LT, liver transplantation; Tx, therapy; CTx, chemotherapy; RTx, radiation therapy; BSC, best supportive care; CSE, conditional survival estimates; 1YR CSE, 1-year CSE; "X"YR or "X"mo, at the time of "X"-year or "X"-month survival.